本帖最后由 老马 于 2012-1-13 21:20 编辑
6 j d1 b* a8 b, h9 s( ~1 U
0 o# g1 D1 l8 \" k爱必妥和阿瓦斯丁的比较
$ g6 \& g* X: v0 g" R8 I- k
7 {1 v3 D" w; X$ [$ Fhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/$ G( h4 C; \ g/ r9 m; F
; W! w! F) T4 Z. d# F( V
6 `6 _) k% b3 _
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ q- I' W8 C2 }5 G5 w( R# b==================================================8 S6 b" u: e2 Y- u/ A+ L
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)1 L o7 _# i- G C' a' s1 A
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) g% Y: e# S: A, K* yResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.8 @! K, O/ y3 y7 J) g& j, j1 R
|